Latest News

FDA Clears VNS Device for Paroxysmal Hemicrania, Hemicrania Continua

Patients treated with gammaCore experienced clinically meaningful benefits.

Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC

Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

Boxing Therapy May Reduce Risk for Falls in Patients With Parkinson Disease

Researchers observed the effect of boxing therapy on overall coordination, gait, and balance in patients with Parkinson disease before, during, and after the COVID-19 lockdown.

Hepatitis D: Recent Advances in Virology, Immunology and Treatment

Forty years after the emergence of HDV, the first anti-HDV therapeutic has been approved by the EMA, indicating the dawn of a new era for this difficult to treat disease

Depression, Anxiety Associated with Osteocalcin, Cortisol in Hyperparathyroidism

Anxiety and depression in people with hyperparathyroidism may be related to levels of 2 key hormones in the body, according to researchers.

Sex-Based Differences in Heart Failure Frailty Explored

This study sought to characterize sex differences in heart failure physical frailty phenotypes.

Improperly Sealed Face Masks May Worsen Moderate to Severe Dry Eye

Researchers found masking can decrease noninvasive tear film breakup time.

Linzagolix NDA Submitted for Uterine Fibroid Treatment

The NDA submission is supported by data from the phase 3 PRIMROSE 1 and PRIMROSE 2 studies, along with data from the 76-week post-treatment follow-up study.

Vitamin K Antagonist Anticoagulants Increase Knee and Hip Osteoarthritis Incidence and Progression Risk

Using the Rotterdam study, researchers examined the effect of vitamin K antagonist anticoagulants, specifically acenocoumarol, on the incidence and progression of hip and knee osteoarthritis.

Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint

The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.

Gut Virome Is Stable Over Time But Varies in Subsets of Patients With IBS

Researchers assessed the stability of the virome over time, the effect of diet and genetics, the impact of the virome on host gene expression, and whether specific viruses are associated with IBS subtypes.

Is Yearly Type 2 Diabetes Screening Cost-Effective for Everyone?

The number of people with type 2 diabetes is expected to be close to 600 million worldwide within the next 10 years, but whether the general public should undergo routine screening is a subject of debate.

CDC: Increase in Adverse Events Linked to Delta-8 THC Products

The delta-8 THC products have not been evaluated or approved by FDA for safe use in any context.

Meloxicam/Rizatriptan Combo Under Review for Migraine Treatment

The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.

FDA: Mandatory Opioid Prescriber Education to Be Discussed at Upcoming Workshop

Overall opioid overdoses and opioid-involved deaths continue to increase.

Ruzurgi Tablets Recalled Due to Yeast, Mold, Bacterial Contamination

The tablets may be contaminated with yeast, mold, and aerobic bacterial.

Hereditary Predisposition Raises Keratoconus Risk

A combination of parental consanguinity, positive family history, and eye rubbing are risks for corneal disease.

Does Anakinra Have a Role in the Treatment of Severe COVID-19?

Authors of a commentary assessed the role of IL-1 receptor antagonism, specifically anakinra, in the treatment of patients with severe COVID-19.

Increased Vitamin D Intake Associated With Reduced Risk for Early-Onset CRC

Investigators examined the association between total vitamin D intake and risk for early-onset colorectal cancer and precursors in women aged less than 50 years.

Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density

The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.